Fredrick B. Hagemeister, Jr, MD, of the University of Texas MD Anderson Cancer Center, discusses whether rituximab maintenance should be used in indolent lymphomas other than follicular.
Steven P. Treon, MD, PhD, of the Dana-Farber Cancer Institute, discusses the question of what is the best upfront therapy for lymphoplasmacytic lymphoma/Waldenström’s macroglobulinemia.
Nathan H. Fowler, MD, of University of Texas MD Anderson Cancer Center, and Sagar Lonial, MD, of the Emory University School of Medicine, discuss managing early relapsing/refractory disease.
Jonathan W. Friedberg, MD, of the University of Rochester Medical Center, discusses the use of rituximab as a single agent and in combination with chemotherapy, the emerging role of novel agents, and some possible explanations for the small subset of patients with inferior outcomes.
James O. Armitage, MD, of the University of Nebraska Medical Center, discusses how an increased understanding of the biology of lymphomas and their multiple subtypes has had a major impact on the ability to treat patients.
Wyndham H. Wilson, MD, PhD, of the National Cancer Institute, discusses the molecular underpinnings of diffuse large B-cell lymphoma and targeted treatments.
